|
|
|
|
 |
Corporate Profile
Æterna Zentaris Inc. (TSX: AEZ, NASDAQ: AEZS) is a late-stage drug development company specialized in oncology and endocrinology.
Contact us:
Æterna Zentaris Inc. 1405 du Parc-Technologique Blvd. Québec, Québec Canada G1P 4P5 Phone: (418) 652-8525 Fax: (418) 652-0881 www.aezsinc.com
|
 |
|
Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with... more...>
Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom’s Macroglobulinemia more...>
|
 |
December 7, 2009 Phase 3 trial results for cetrorelix in BPH More |
 |
Download PDF (67K) |
| Download and install Acrobat Reader 6.0. |
|
|
 |